- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06840886
진행된 고형 종양에서의 PHST001에 대한 연구
개방형-라벨, 1A/1B, 용량 에스컬레이션 및 용량 확장 연구, 진보 된 재발 및/또는 내화성 고형 종양을 가진 성인 환자에서 PHST001의 안전, 약동학, 약력학 및 항 종양 활성을 조사하는 연구.
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.
The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: Raphaël Rousseau, Chief Medical Officer, PhD, MD
- 전화번호: 650-260-8443
- 이메일: medical@pheast.com
연구 장소
-
-
California
-
Beverly Hills, California, 미국, 90212
- 모병
- Precision NextGen Oncology & Research Center
-
연락하다:
- Jing Liu
- 전화번호: 424-777-0708
- 이메일: JingL@nextgenonc.com, research@nextgenonc.com
-
수석 연구원:
- Kamlesh Kumar Sankhala, MD
-
Los Angeles, California, 미국, 90033
- 모병
- USC Norris Comprehensive Cancer Center
-
연락하다:
- Lorraine Martinez
- 이메일: Lorraine.Martinez@med.usc.edu
-
연락하다:
- Stephanie Kim
- 이메일: Stephanie.Kim2@med.usc.edu
-
Palo Alto, California, 미국, 94304
- 모병
- Stanford University School of Medicine
-
연락하다:
- Kayla McDaniel
- 전화번호: 650-498-7293
- 이메일: mcda59@stanford.edu
-
수석 연구원:
- Oliver Dorigo, MD, PhD
-
-
Colorado
-
Denver, Colorado, 미국, 80218
- 모병
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
-
연락하다:
- Sarah Cannon Research Institute at HCA HealthONE
- 전화번호: 720-754-2610
- 이메일: CANN.DDUDenverGeneral@SarahCannon.com
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06520
- 모병
- Yale Cancer Center
-
수석 연구원:
- Michael Cecchini, MD
-
연락하다:
- Priscilla Stéve
- 전화번호: 203-464-5564
- 이메일: Priscilla.steve@yale.edu
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana Farber Cancer Institute
-
수석 연구원:
- Michael Dennis, MD
-
연락하다:
- DFCI CCTI Referrals
- 이메일: dfcicctiexternalreferral@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan Rogel Cancer Center
-
수석 연구원:
- Ulka Vaishampayan, MD
-
연락하다:
- University of Michigan Health Cancer AnswerLine
- 전화번호: 1-800-865-1125
- 이메일: canceranswerline@med.umich.edu
-
Grand Rapids, Michigan, 미국, 49546
- 모병
- START Center for Cancer Research - Midwest
-
수석 연구원:
- Sreenivasa Chandana, MD, PhD
-
연락하다:
- START HOPE Team
- 이메일: hopeteam@startresearch.com
-
-
New York
-
Lake Success, New York, 미국, 11042
- 모병
- START Center for Cancer Research - Long Island New York
-
수석 연구원:
- Geraldine O'Sullivan Coyne, MD
-
연락하다:
- Sadia Morium
- 전화번호: 363-207-5166
- 이메일: sadia.morium@startresearch.com
-
New York, New York, 미국, 10029
- 모병
- Mount Sinai
-
수석 연구원:
- Thomas Marron, MD, PhD
-
연락하다:
- Jordan Cuevas
- 전화번호: 212-824-7945
- 이메일: jordan.cuevas@mssm.edu
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke Cancer Institute
-
연락하다:
- Phase 1 and Immunotherapy Team
- 전화번호: 919-684-6342
- 이메일: Phase1andImmunotherapyreferrals@duke.edu
-
수석 연구원:
- Niharika Mettu, MD, PhD
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Vanderbilt-Ingram Cancer Center
-
연락하다:
- Clinical Trials Office (CTO)
- 전화번호: 1-800-811-8480
- 이메일: cip@vumc.org
-
수석 연구원:
- Elizabeth Davis, MD, PhD
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute (SCRI) Oncology Partners
-
수석 연구원:
- Deepak Bhamidipati, MD
-
연락하다:
- SCRI Oncology Partners - Nashville
- 전화번호: 1-877-MY-1-SCRI (691-7274)
- 이메일: ASKSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- 모병
- START Center for Cancer Research - Texas
-
연락하다:
- START HOPE Team
- 이메일: hopeteam@startresearch.com
-
수석 연구원:
- Henry Xiong, MD, PhD
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson Cancer Center
-
연락하다:
- MD Anderson Cancer Center
- 전화번호: 713-563-1930
- 이메일: ICTNPCS@mdanderson.org
-
수석 연구원:
- Stéphane Champiat, MD, PhD
-
Irving, Texas, 미국, 75039
- 모병
- NEXT Oncology - Dallas
-
수석 연구원:
- Michael Song, MD, PhD, PharmD
-
연락하다:
- NEXT Referrals-Dallas
- 전화번호: fax: 210-568-4577
- 이메일: nxt_txreferrals@nextoncology.com
-
San Antonio, Texas, 미국, 78229
- 모병
- University of Texas (UT) Health
-
수석 연구원:
- Daruka Mahadevan, MD, PhD
-
연락하다:
- Mays Cancer Center Research Team
- 이메일: mccresearch@uthscsa.edu
-
San Antonio, Texas, 미국, 78229
- 모병
- START Center for Cancer Research - San Antonio
-
수석 연구원:
- Kyriakos Papadopoulos, MD
-
연락하다:
- START HOPE Team
- 전화번호: 210-593-5250
- 이메일: hopeteam@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- NEXT Oncology - Virginia
-
연락하다:
- Carrie Friedman
- 이메일: adelgado@nextoncology.com
-
연락하다:
- Allison Delgado
- 이메일: carrie.friedman@usoncology.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
- Adequate organ function per laboratory testing
- Pregnancy prevention requirements
- Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
Key Exclusion Criteria:
- Diagnosis of immunodeficiency
- History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
- Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
- Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
- Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
- Received previous treatment with another agent targeting CD24.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: PHST001 Monotherapy
Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. |
|
실험적: PHST001 + Paclitaxel
Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Paclitaxel used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + Topotecan
Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Topotecan used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + Doxorubicin
Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Doxorubicin used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + FOLFIRI
Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFIRI used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + FOLFOX
Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFOX used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + Gemcitabine
Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Gemcitabine used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + Mirvetuximab Soravtansine
Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Mirvetuximab soravtansine used as per standard of care.
다른 이름들:
|
|
실험적: PHST001 + Trastuzumab Deruxtecan
Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Trastuzumab deruxtecan used as per standard of care.
다른 이름들:
|
|
활성 비교기: Mirvetuximab Soravtansine Monotherapy
Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy. |
Mirvetuximab soravtansine used as per standard of care.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose of PHST001 through 21 days after the first dose of PHST001
|
Based on toxicities observed |
From first dose of PHST001 through 21 days after the first dose of PHST001
|
|
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From signed consent up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From signed consent up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
기간: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
기간: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
기간: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
기간: From screening and during treatment up to 2 years
|
Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression. |
From screening and during treatment up to 2 years
|
|
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
기간: From screening and during treatment up to 2 years
|
Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
기간: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
|
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
기간: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to the date of death. |
From screening and during treatment up to 2 years
|
|
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
기간: From treatment until 90 days after last dose of PHST001
|
Defined as the maximum blood concentration of a dose of PHST001 |
From treatment until 90 days after last dose of PHST001
|
|
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001
|
Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration. |
From treatment until 90 days after last dose of PHST001
|
|
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001
|
Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration). |
From treatment until 90 days after last dose of PHST001
|
|
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001
|
Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile. |
From treatment until 90 days after last dose of PHST001
|
|
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001
|
Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered. |
From treatment until 90 days after last dose of PHST001
|
|
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001
|
Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream. |
From treatment until 90 days after last dose of PHST001
|
|
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
기간: From treatment until 90 days after last dose of PHST001
|
Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination. |
From treatment until 90 days after last dose of PHST001
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 생식기 질환
- 내분비계 질환
- 신경계 질환
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 조직학적 유형에 따른 신생물
- 자궁 질환
- 생식기 질환, 여성
- 내분비샘 신생물
- 신생물, 선상 및 상피
- 선암종
- 난소 질환
- 부속기 질환
- 생식기 신생물, 여성
- 생식선 장애
- 피부병
- 유방 질환
- 암종
- 신경계 신생물
- 자궁 신생물
- 육종
- 신생물, 결합 및 연조직
- 신생물, 복합 및 혼합
- 나팔관 질환
- 피부 및 결합 조직 질환
- 난소 신생물
- 유방 신생물
- 담관암
- 자궁내막 신생물
- 암육종
- 중추신경계 신생물
- 나팔관 신생물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 탄화수소
- 사이클로 파라핀
- 탄화수소, alicyclic
- 탄화수소, 순환
- 테르펜
- 탄수화물
- Camptothecin
- 알칼로이드
- 다 환식 방향족 탄화수소
- 탄화수소, 방향족
- 다 환식 화합물
- 글리코 사이드
- 효소 및 코엔자임
- 박습니다
- 사이클로 데카네
- Diterpenes
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- Formyltetrahydrofolates
- 테트라 하이드로 폴 레이트
- 엽산
- Pterins
- Teridines
- 우라실
- 피리 미디 논
- 안트라 사이클린
- 나프 타센
- 아미노 글리코 시드
- 코엔자임
- Daunorubicin
- 젬시타빈
- 플루오로우라실
- 류코보린
- 독소루비신
- 파클리탁셀
- 토포테칸
- Mirvetuximab Soravtansine
- Trastuzumab deruxtecan
- Folfox 프로토콜
- IFL 프로토콜
기타 연구 ID 번호
- PHST001-101
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .